We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- COPD case study: patient KM
- COPD case study: KM history
- PFTs
- Chest CT
- Combined assessment of COPD
- Therapeutic options: COPD medications
- Pharmacologic therapy (1)
- KM’s past and current treatment
- Pharmacologic options (1)
- Suitability of proposed treatment strategies
- Managing KM’s progressive COPD
- Changing delivery devices
- Factors to consider when selecting delivery devices
- Changes in FEV1 at 2 hr
- Fluticasone vs. Budesonide
- ICS and risk of pneumonia for COPD
- Fluticasone vs. Budesonide: dosage
- KM follow up
- Pharmacologic options (2)
- Dual bronchodilators: LAMA/LABA
- Trial of roflumilast
- Efficacy of roflumilast in the COPD
- Roflumilast: patients with severe COPD
- Pharmacologic options (3)
- Trial of N-acetylcysteine (NAC)
- Trial of NAC
- Daily Rx with azithromycin
- COPD study participants
- Concerns with drugs
- Prophylactic antibiotic trials
- Azithromycin/Placebo hazard ratios
- Responses to daily azithromycin therapy
- Pharmacologic therapy (2)
- Theophylline
- Non-pharmacologic management
Topics Covered
- COPD case study
- Combined assessment of COPD
- Therapeutic options: COPD medications
- Advantages, limitations, and concerns about available therapy for COPD
- Combination therapies
- Risk factors for progression, COPD exacerbations, and complications with current therapy
- Update talk: COPD medications
- Update talk: Mono vs. dual vs. triple therapy in COPD
- Update talk: Role of ICS in COPD
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Chatila, W. (2021, September 30). Tailoring care for advanced COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/MHNT8169.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Wissam Chatila has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 48:10 min
- Update Duration: 22:56 min
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
I'm presenting a COPD case study,
my name is Wissam Chatila.
KM is a 58 year-old man diagnosed with emphysema in 2010,
0:06
he presents to my clinic for a second opinion for management of his COPD.
He has no significant past medical history,
he has no prior history of cardiovascular disease or metabolic diseases.
He is a retired airport technician and a former smoker, he had quit one year previously.
There was no other history of illicit drug use and/or prior exposures.
Family history is significant for a brother who has history of asthma.
0:45
He had three exacerbations per year over the last two or three years,
some requiring hospitalization.
He had two pneumonias over the last two years in addition to his exacerbations.
He has no wheezing by history
but has a slight cough,
minimally productive with occasional clear mucus production.
His mMRC score is 3,
that is, he is breathless with mild-to-moderate activity,
he stops for breath after walking a hundred yards or after a few minutes on level ground.
He gets substantial relief with the use of
albuterol nebulizer treatments that he takes three or four times per day.
1:34
This slide shows his pulmonary function tests.
The first ones were done in May 2012 by his pulmonologist.
His vital capacity was 105,
FEV1 33 percent, and his FEV1/FVC ratio is
25 percent, significant for very severe obstruction.
Air trapping (his TLC) is 128, and RV is 209,
so he's significantly hyperinflated and air-trapped.
The most recent pulmonary function test shows a significant deterioration
in his air-flow obstruction, with an FEV1 of 17 percent compared to the previous 33 percent,
so he continues to be very severe and much worse compared to 2012.
His hyperinflation and air-trapping have also progressed, with a TLC of
138 percent and RV of 295 percent.
His DLCO is also severely reduced to 22 percent.
On the six-minute walk distance he walked 165 meters, his lowest oxygen saturation was 80 percent,
and he required six liters per minute to maintain an oxygen saturation above 90 percent.
His arterial blood gas does not show significant hypercapnia,
but he was hypoxemic with a PO2 of 65.